vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 9.5%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
ESPR vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $220.8M |
| Net Profit | — | $12.8M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 7.1% |
| Net Margin | — | 5.8% |
| Revenue YoY | 143.7% | 9.6% |
| Net Profit YoY | — | -42.1% |
| EPS (diluted) | $0.32 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $220.8M | ||
| Q3 25 | $87.3M | $222.4M | ||
| Q2 25 | $82.4M | $204.3M | ||
| Q1 25 | $65.0M | $207.4M | ||
| Q4 24 | $69.1M | $201.4M | ||
| Q3 24 | $51.6M | $196.4M | ||
| Q2 24 | $73.8M | $177.5M | ||
| Q1 24 | $137.7M | $184.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | $-31.3M | $18.8M | ||
| Q2 25 | $-12.7M | $10.7M | ||
| Q1 25 | $-40.5M | $11.4M | ||
| Q4 24 | — | $22.2M | ||
| Q3 24 | $-29.5M | $18.8M | ||
| Q2 24 | $-61.9M | $5.0M | ||
| Q1 24 | $61.0M | $7.8M |
| Q4 25 | 50.6% | 7.1% | ||
| Q3 25 | -11.4% | 11.2% | ||
| Q2 25 | 8.6% | 6.9% | ||
| Q1 25 | -34.0% | 8.1% | ||
| Q4 24 | -6.4% | 13.6% | ||
| Q3 24 | -31.0% | 13.3% | ||
| Q2 24 | 3.5% | 4.2% | ||
| Q1 24 | 52.5% | 6.1% |
| Q4 25 | — | 5.8% | ||
| Q3 25 | -35.9% | 8.4% | ||
| Q2 25 | -15.4% | 5.2% | ||
| Q1 25 | -62.2% | 5.5% | ||
| Q4 24 | — | 11.0% | ||
| Q3 24 | -57.2% | 9.6% | ||
| Q2 24 | -83.9% | 2.8% | ||
| Q1 24 | 44.3% | 4.2% |
| Q4 25 | $0.32 | $0.23 | ||
| Q3 25 | $-0.16 | $0.33 | ||
| Q2 25 | $-0.06 | $0.19 | ||
| Q1 25 | $-0.21 | $0.21 | ||
| Q4 24 | $-0.14 | $0.40 | ||
| Q3 24 | $-0.15 | $0.35 | ||
| Q2 24 | $-0.33 | $0.09 | ||
| Q1 24 | $0.34 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $162.8M |
| Total DebtLower is stronger | — | $101.4M |
| Stockholders' EquityBook value | $-302.0M | $335.9M |
| Total Assets | $465.9M | $834.0M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $162.8M | ||
| Q3 25 | $92.4M | $169.1M | ||
| Q2 25 | $86.1M | $70.7M | ||
| Q1 25 | $114.6M | $96.0M | ||
| Q4 24 | $144.8M | $172.0M | ||
| Q3 24 | $144.7M | $161.9M | ||
| Q2 24 | $189.3M | $115.5M | ||
| Q1 24 | $226.6M | $116.1M |
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $-302.0M | $335.9M | ||
| Q3 25 | $-451.4M | $328.1M | ||
| Q2 25 | $-433.5M | $306.8M | ||
| Q1 25 | $-426.2M | $293.9M | ||
| Q4 24 | $-388.7M | $280.0M | ||
| Q3 24 | $-370.2M | $260.2M | ||
| Q2 24 | $-344.2M | $239.4M | ||
| Q1 24 | $-294.3M | $232.6M |
| Q4 25 | $465.9M | $834.0M | ||
| Q3 25 | $364.0M | $826.1M | ||
| Q2 25 | $347.1M | $740.8M | ||
| Q1 25 | $324.0M | $720.4M | ||
| Q4 24 | $343.8M | $753.8M | ||
| Q3 24 | $314.1M | $744.6M | ||
| Q2 24 | $352.3M | $706.0M | ||
| Q1 24 | $373.1M | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $3.1M |
| Free Cash FlowOCF − Capex | — | $-19.2M |
| FCF MarginFCF / Revenue | — | -8.7% |
| Capex IntensityCapex / Revenue | 0.0% | 10.1% |
| Cash ConversionOCF / Net Profit | — | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | — | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $3.1M | ||
| Q3 25 | $-4.3M | $57.1M | ||
| Q2 25 | $-31.4M | $18.1M | ||
| Q1 25 | $-22.6M | $-789.0K | ||
| Q4 24 | $-35.0M | $23.0M | ||
| Q3 24 | $-35.3M | $67.5M | ||
| Q2 24 | $-7.2M | $10.0M | ||
| Q1 24 | $53.8M | $-2.5M |
| Q4 25 | — | $-19.2M | ||
| Q3 25 | — | $40.6M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $-11.7M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | $-35.5M | $60.0M | ||
| Q2 24 | $-7.3M | $3.0M | ||
| Q1 24 | $53.8M | $-8.4M |
| Q4 25 | — | -8.7% | ||
| Q3 25 | — | 18.3% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | -5.7% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | -68.7% | 30.6% | ||
| Q2 24 | -9.9% | 1.7% | ||
| Q1 24 | 39.0% | -4.6% |
| Q4 25 | 0.0% | 10.1% | ||
| Q3 25 | 0.0% | 7.4% | ||
| Q2 25 | 0.0% | 5.5% | ||
| Q1 25 | 0.0% | 5.3% | ||
| Q4 24 | 0.0% | 1.7% | ||
| Q3 24 | 0.3% | 3.8% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | 0.1% | 3.2% |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× | ||
| Q1 24 | 0.88× | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
